DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 18-956/SLR-049

Amersham Health
Attention: Paula Clark
Associate, Regulatory Affairs
101 Carnegie Center
Princeton, NJ 08540-6231

Dear Ms. Clark:

Please refer to your supplemental new drug application dated July 12, 1996, received July 15, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Omnipaque® (iohexol) Injection.

This "Changes Being Effected" supplemental new drug application provides for the addition of the following statement to the **PRECAUTIONS-General** sections (after the seventh paragraph on page 2 and after the third paragraph on page 6) of the labeling:

> "Parenteral use of iodinated contrast agents may result in a transient impairment in renal function. The accumulation of biguanides (GLUCOPHAGE® - metformin) secondary to renal dysfunction has been associated with an increased risk of developing lactic acidosis. When lactic acidosis has occurred during treatment with GLUCOPHAGE it has been reported to be fatal in approximately 50% of cases (See GLUCOPHAGE circular). Biguanides should be withheld for at least 48 hours prior to, and 48 hours after administration of iodinated contrast media. Biguanide therapy should only be resumed after renal function has been re-evaluated and found to be satisfactory."

We completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must include all previous revisions as reflected in the most recently approved package insert.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 18-956/SLR-049." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lynn Panholzer, Pharm.D., Regulatory Project Manager, at (301) 827-3247.

Sincerely,

{See appended electronic signature page}

Patricia Y. Love, M.D., M.B.A.
Director
Division of Medical Imaging and Radiopharmaceutical Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Patricia Love

12/23/02 10:25:24 AM